Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10490820 | 0.89 | MEN1 (0.38) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL5403745 | 0.84 | MEN1 (0.44) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL22488345 | 0.83 | MEN1 (0.42) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL18888509 | 0.82 | KMT2A (0.45) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL24391385 | 0.81 | MEN1 (0.41) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL28434155 | 0.80 | MEN1 (0.41) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL22728173 | 0.78 | MEN1 (0.47) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL5410764 | 0.78 | SERPINE1 (0.40) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL6563149 | 0.77 | MEN1 (0.50) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL1105702 | 0.77 | PCSK9 (0.50) | MEN1GAAKMT2ATDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4637833-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | Genentech, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024138128-A2 | CEREBLON DEGRADER CONJUGATES, AND USES THEREOF | GENENTECH, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-11090322-B2 | Anthracycline disulfide intermediates, antibody-drug conjugates and methods | GENENTECH, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| CN-106565696-B | Oxadiazole derivative, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-3191134-B1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190054102-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-20160074528-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | GENENTECH, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| EP-1888567-B1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1888567-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis (FR) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122661-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054102-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | PDIA5, PDIA4, PDIA6 | MEN1 4005/4885GAA 3291/4885KMT2A 2584/4885 |
| US-11090322-B2 | Anthracycline disulfide intermediates, antibody-drug conjugates and methods | PDIA5, PDIA4, PDIA6 | MEN1 4005/4885GAA 3291/4885KMT2A 2584/4885 |
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | TFPI, SERPINC1, PLAT | MEN1 4624/4885GAA 701/4885KMT2A 3228/4885 |
| US-20160074528-A1 | ANTHRACYCLINE DISULFIDE INTERMEDIATES, ANTIBODY-DRUG CONJUGATES AND METHODS | PDIA5, PDIA4, PDIA6 | MEN1 4005/4885GAA 3291/4885KMT2A 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.